# Starling Oncology, Inc. (TOI) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Starling Oncology, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/TOI/mda/fy2025/): filed 2026-03-12; accession 0001799191-26-000007 (https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/toi-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/TOI/mda/fy2024/): filed 2025-03-26; accession 0001799191-25-000014 (https://www.sec.gov/Archives/edgar/data/1799191/000179919125000014/toi-20241231.htm)
- [FY 2023 MD&A](/company/TOI/mda/fy2023/): filed 2024-03-28; accession 0001628280-24-013444 (https://www.sec.gov/Archives/edgar/data/1799191/000162828024013444/toi-20231231.htm)
- [FY 2022 MD&A](/company/TOI/mda/fy2022/): filed 2023-03-16; accession 0001628280-23-008315 (https://www.sec.gov/Archives/edgar/data/1799191/000162828023008315/toi-20221231.htm)
- [FY 2021 MD&A](/company/TOI/mda/fy2021/): filed 2022-03-11; accession 0001628280-22-005868 (https://www.sec.gov/Archives/edgar/data/1799191/000162828022005868/toi-20211231.htm)

Back to /company/TOI/